Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion ...

MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.

Verona brings with it Ohtuvayre, an inhaled treatment for chronic obstructive pulmonary disease, often known as smoker's lung ...

Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

We recently published Jim Cramer Analyzed These 9 Stocks As He Said Tariffs Are Better Than CIA Coups. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc ...

Merck says it will acquire London-based Verona Pharma for about US$10bil, gaining a promising respiratory treatment as it ...

Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.